title: Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis.
abstract: We immunohistochemically examined the expression of the glucose transporters (GLUT)1, GLUT3 and GLUT4, in 154 tumor samples of epithelial ovarian carcinoma. In addition, we investigated the correlations between the expression of GLUTs and the vascular endothelial growth factor (VEGF), and microvessel count and clinical parameters. The rates of expression of GLUT1, GLUT3 and GLUT4 were 98.7%, 92.8% and 84.4%, respectively. GLUT1 and GLUT4 were both strongly expressed in serous adenocarcinoma, but weakly expressed in clear cell adenocarcinoma. The expressions of GLUT1 and GLUT4 correlated with the clinical disease stage. The expressions of GLUT1, GLUT3 and GLUT4 correlated positively with VEGF expression. The expression status for GLUT1, GLUT3, GLUT4 and VEGF did not represent a prognostic factor. These findings suggest that characteristic differences in the patterns of glucose uptake can exist according to the histological type and that GLUT1, GLUT3 and GLUT4 could be related to tumor angiogenesis in epithelial ovarian carcinoma.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
authors.forename: Miho
authors.initials: M
authors.lastname: Tsukioka
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Maiko
authors.initials: M
authors.lastname: Noriyuki
authors.forename: Chika
authors.initials: C
authors.lastname: Yoshida
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nobeyama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshida
authors.forename: Tomoyo
authors.initials: T
authors.lastname: Yasui
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Sumi
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Honda
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishiko
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism / Q000473:pathology; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D051272:Glucose Transporter Type 1 / Q000096:biosynthesis*; D051274:Glucose Transporter Type 3 / Q000096:biosynthesis*; D051275:Glucose Transporter Type 4 / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis
chemical_list: D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D051275:Glucose Transporter Type 4; C495677:SLC2A1 protein, human; C495687:SLC2A3 protein, human; C495692:SLC2A4 protein, human; D042461:Vascular Endothelial Growth Factor A